Company news
Oncopeptides AB news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe
May 26, 2026
Oncopeptides (Q1 Update): Strong Quarterly Growth and Decreased Costs
May 20, 2026
Oncopeptides secures regulatory approval to start Window-of-Opportunity study in glioblastoma from Norwegian authorities
May 19, 2026
Oncopeptides publishes Q1 report 2026
May 13, 2026
Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment
May 11, 2026
Invitation to presentation of the Q1 report 2026
May 6, 2026
Oncopeptides publishes the 2025 Annual Report
April 28, 2026
Calls
The 5 newest of 10 calls. Every call is listed under its year.
- Oncopeptides (Stockholm:ONCO) Q2 2026 Earnings Call
Aug 27, 2026
Transcript - Oncopeptides (Stockholm:ONCO) Q1 2026 Earnings Call
May 13, 2026
Transcript - Oncopeptides (Stockholm:ONCO) Q4 2025 Earnings Call
Feb 19, 2026
Transcript - Oncopeptides (Stockholm:ONCO) Q3 2025 Earnings Call
Nov 5, 2025
Transcript - Oncopeptides (Stockholm:ONCO) Q2 2025 Earnings Call
Aug 21, 2025
Transcript
Decks
The 5 newest of 13 decks. Every deck is listed under its year.
- Q2 2026 Earnings Presentation
Earnings · 34 slides · Aug 27, 2026
- Type II application Investor conference (May 2026)
Conference · 29 slides · May 11, 2026
- Shareholder Meeting (May 2026)
Shareholder meeting · 60 slides · May 2026
- Q4 2025 Earnings Presentation
Earnings · 26 slides · Feb 19, 2026
- Q3 2025 Earnings Presentation
Earnings · 30 slides · Nov 5, 2025